Selective internal radiation therapy
Ask the expert
The report presents a summary of reimbursement situation for selective internal radiation therapy in Europe.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
The following indications will be considered:
- Primary liver cancer (hepatocellular carcinoma);
- Metastatic liver cancer.
Different types of microspheres for SIRT will be covered in the report, including those use the radionuclide yttrium-90 and based on the radionuclide holmium-166.
The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- France
- Germany
- Italy
- Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of treatment of selective internal radiation therapy (SIRT):
- Bio-Rad (Bio-Rex, Aminex)
- BTG (TheraSphere)
- Sirtex (Sir-spheres)
- Terumo (QuiremScout, QuiremSpheres)
Table of content is not available at the moment. Report is still ongoing.
23
Mar 2023
In February 2023, the Scottish Health Technology Group, SHTG, released three MedTech-related assessments: selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma, Feeling Good app, store-and-forward teledermatology for triage of primary care referrals.
Read more16
Mar 2023
In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.
Read more24
Feb 2023
In February 2023, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 188 and 084 with changes to be implemented no later than March 23, 2023. Five new procedure codes (concerning interventional radiology, robotic surgery, and radiotherapy) and one new diagnostic code were introduced.
Read more15
Feb 2023
In February 2023, it was announced that the Basque Office for Health Technology Assessment (OSTEBA) initiated several HTAs, including evaluations in the e-health, radiology, nephrology and urology, cardiovascular, IVD, obstetrics and gynecology, diagnostic imaging, radiotherapy, neurovascular, ENT, interventional radiology, surgical procedures, and some other fields.
Read more12
Jan 2023
In December 2022, the National Institute for Health and Care Excellence (NICE) published one new Medical Technologies Guidance (Memokath 051 Ureter stent for ureteric obstruction) and one MedTech Innovation Briefing (PromarkerD). Also, two new clinical guidelines were published, and one was updated.
Read more